Illumina, Inc. and Wellcome Trust Sanger Institute Announce Completed Genome for Endangered Tasmanian Devil

SAN DIEGO--(BUSINESS WIRE)--Researchers from Illumina, Inc. (NASDAQ:ILMN) and the Wellcome Trust Sanger Institute have used Illumina’s next generation sequencing technology to create a draft genome sequence for the endangered Tasmanian devil, and will use this to find genetic mutations in the transmissible cancer that is ravaging its population.

Back to news